Literature DB >> 16616557

Vitamin C and vitamin E in pregnant women at risk for pre-eclampsia (VIP trial): randomised placebo-controlled trial.

L Poston1, A L Briley, P T Seed, F J Kelly, A H Shennan.   

Abstract

BACKGROUND: Oxidative stress could play a part in pre-eclampsia, and there is some evidence to suggest that vitamin C and vitamin E supplements could reduce the risk of the disorder. Our aim was to investigate the potential benefit of these antioxidants in a cohort of women with a range of clinical risk factors.
METHODS: We did a randomised, placebo-controlled trial to which we enrolled 2410 women identified as at increased risk of pre-eclampsia from 25 hospitals. We assigned the women 1000 mg vitamin C and 400 IU vitamin E (RRR alpha tocopherol; n=1199) or matched placebo (n=1205) daily from the second trimester of pregnancy until delivery. Our primary endpoint was pre-eclampsia, and our main secondary endpoints were low birthweight (<2.5 kg) and small size for gestational age (<5th customised birthweight centile). Analyses were by intention to treat. This study is registered as an International Standard Randomised Controlled Trial, number ISRCTN 62368611 .
FINDINGS: Of 2404 patients treated, we analysed 2395 (99.6%). The incidence of pre-eclampsia was similar in treatment placebo groups (15% [n=181] vs 16% [n=187], RR 0.97 [95% CI 0.80-1.17]). More low birthweight babies were born to women who took antioxidants than to controls (28% [n=387] vs 24% [n=335], 1.15 [1.02-1.30]), but small size for gestational age did not differ between groups (21% [n=294] vs 19% [n=259], 1.12 [0.96-1.31]).
INTERPRETATION: Concomitant supplementation with vitamin C and vitamin E does not prevent pre-eclampsia in women at risk, but does increase the rate of babies born with a low birthweight. As such, use of these high-dose antioxidants is not justified in pregnancy.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16616557     DOI: 10.1016/S0140-6736(06)68433-X

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  154 in total

1.  Endothelial dysfunction. An important mediator in the pathophysiology of hypertension during pre-eclampsia.

Authors:  B Lamarca
Journal:  Minerva Ginecol       Date:  2012-08

2.  The role of immune activation in contributing to vascular dysfunction and the pathophysiology of hypertension during preeclampsia.

Authors:  B Lamarca
Journal:  Minerva Ginecol       Date:  2010-04

3.  Role of reactive oxygen species during hypertension in response to chronic antiangiogenic factor (sFlt-1) excess in pregnant rats.

Authors:  Kiran B Tam Tam; Babbette Lamarca; Marietta Arany; Kathy Cockrell; Lillian Fournier; Sydney Murphy; James N Martin; Joey P Granger
Journal:  Am J Hypertens       Date:  2010-08-19       Impact factor: 2.689

4.  Plasma vitamin C concentration in pregnant women with pre-eclampsia in Mulago hospital, Kampala, Uganda.

Authors:  P Kiondo; G Welishe; J Wandabwa; G Wamuyu-Maina; G S Bimenya; P Okong
Journal:  Afr Health Sci       Date:  2011-12       Impact factor: 0.927

Review 5.  Developmental aspects of a life course approach to healthy ageing.

Authors:  M A Hanson; C Cooper; A Aihie Sayer; R J Eendebak; G F Clough; J R Beard
Journal:  J Physiol       Date:  2016-02-04       Impact factor: 5.182

6.  Vascular endothelial mitochondrial oxidative stress in response to preeclampsia: a role for angiotension II type 1 autoantibodies.

Authors:  Evangeline Deer; V Ramana Vaka; Kristen M McMaster; Kedra Wallace; Denise C Cornelius; Lorena M Amaral; Mark W Cunningham; Babbette LaMarca
Journal:  Am J Obstet Gynecol MFM       Date:  2020-10-27

7.  Ascorbate prevents placental oxidative stress and enhances birth weight in hypoxic pregnancy in rats.

Authors:  H G Richter; E J Camm; B N Modi; F Naeem; C M Cross; T Cindrova-Davies; O Spasic-Boskovic; C Dunster; I S Mudway; F J Kelly; G J Burton; L Poston; D A Giussani
Journal:  J Physiol       Date:  2012-01-30       Impact factor: 5.182

8.  New Insights into the Pathogenesis of Preeclampsia - The Role of Nrf2 Activators and their Potential Therapeutic Impact.

Authors:  N Kweider; C J Wruck; W Rath
Journal:  Geburtshilfe Frauenheilkd       Date:  2013-12       Impact factor: 2.915

Review 9.  Are we getting closer to a Nobel prize for unraveling preeclampsia?

Authors:  Ralf Dechend; Friedrich C Luft
Journal:  Curr Cardiol Rep       Date:  2008-11       Impact factor: 2.931

10.  A prospective cohort study of the value of maternal plasma concentrations of angiogenic and anti-angiogenic factors in early pregnancy and midtrimester in the identification of patients destined to develop preeclampsia.

Authors:  Juan Pedro Kusanovic; Roberto Romero; Tinnakorn Chaiworapongsa; Offer Erez; Pooja Mittal; Edi Vaisbuch; Shali Mazaki-Tovi; Francesca Gotsch; Samuel S Edwin; Ricardo Gomez; Lami Yeo; Agustin Conde-Agudelo; Sonia S Hassan
Journal:  J Matern Fetal Neonatal Med       Date:  2009-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.